Depressive Symptoms in Parkinson Disease as Measured by Beck's Depression Scale and Its Relationship to Visual Analogue Mood Scale, Motor Symptoms and the Quality of Life Measures (P06.057)

Abstract

Objective: To ascertain the relationship between depression score and visual analogue mood scale, quality of life and motor severity in Parkinson9s disease. Background Depression is the most common non-motor manifestation of Parkinson disease (PD), affecting up to 40 to 50 % of PD patients, far in excess of its prevalence of 6.7% in the general American population. Design/Methods: All patients seen at the University of Florida Movement Disorders Center, with a confirmed PD diagnosis and a recorded Beck Depression Inventory (BDI) on their first visit were included in this study. Using a cutoff of 14, we determined the prevalence of depressive symptoms in our whole population, in men versus women and in drug naive versus those treated with levodopa. Results: The depressed cohort had a mean BDI score of 19.41 whereas the mean for the non-depressed was 7.06. The HY with the last two having negative coefficients. The best predictor, not surprisingly was the SadTscore. Overall there is not a strong correlation between VAMS and BDI. Conclusions: There is a correlation between the severity of motor symptoms and the presence of depression pointing to the possibility of both organic and reactive components in PD depression. There was only poor correlation between the VAMS score and BDI, but the quality of life PDQ-39 paralleled the BDI score raising questions whether this is cause or effect. Disclosure: Dr. Salardini has nothing to disclose. Dr. Rodriguez has received personal compensation for activities with Allergan, Merz Pharmaceuticals, Lundbeck and Teva Pharmaceuticals as a consultant. Dr. Malaty has received research support from The National Parkinson Foundation. Dr. Okun has received personal compensation for activities with National Parkinson Foundation, Ask the Expert, and Neuropace Devices. Dr. Okun has received research support from the Michael J. Fox Foundation, the National Parkinson Foundation, the Parkinson Alliance and the National Institutes of Health. Dr. Fernandez has received personal compensation for activities with USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, and US World Meds Dr. Fernandez has received personal compensation in an editorial capacity for the Movement Disorders Society Website. Dr. Fernandez has received royalty payments from Demos Publishing, Manson Publishing, and Springer Publishing. Dr. Fernandez has received research support from Abbott, Acadia, Biotie Therapeutics, EMD-Serono, Huntington Study Group, Ipsen, Merz Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, National Parkinson Foundation, NIH/NINDS, Novartis, Parkinson Study Group, Teva, but has no owner interest in any pharmaceutical company.